Does Dr. HEIDAR ALBANDAR have financial conflicts of interest?

Dr. HEIDAR ALBANDAR (MD) has received a total of $5,778 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $5,778 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. HEIDAR ALBANDAR?

According to CMS Open Payments data, Dr. HEIDAR ALBANDAR received funding from EXELIXIS ($3,640), DAIICHI SANKYO ($221), and NOVARTIS PHARMACEUTICALS CORPORATION ($213).

Does Dr. HEIDAR ALBANDAR receive research grants or speaking fees?

Dr. HEIDAR ALBANDAR has received $5,778 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. HEIDAR ALBANDAR

MDReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: FOUNTAIN HILL, PA 18015

NPI Number: 1659766889

LIFETIME INDUSTRY VALUE

$5,778

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ALBANDAR is a verified Internal Medicine, Medical Oncology practitioner based in FOUNTAIN HILL, PA.

Between 2021 and 2025, Dr. ALBANDAR had an overall industry promotional and research financial footprint of $5,778 as recorded in the federal CMS Open Payments database.

$5,778 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ALBANDAR's primary funding source is EXELIXIS, which accounts for $3,640 (representing 63% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

EXELIXIS

Rank 1

$3,640

63%

DAIICHI SANKYO

Rank 2

$221

3.8%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 3

$213

3.7%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.